News

Lyon, France, April 22nd, 2026 – OREGA Biotech is pleased to announce that interim results from the Phase 2 MATISSE trial evaluating IPH5201, a first-in-class CD39 blocking monoclonal antibody, in combination with durvalumab and platinum-based chemotherapy in patients with resectable early-stage non-small cell lung cancer (NSCLC) were presented on April 21st during a plenary session at AACR 2026 by Professor Fabrice Barlesi (Gustave Roussy) and discussed by Professor Tina Cascone (MD Anderson). Presentation highlights: Perioperative PD-(L)1 inhibitors combined with chemotherapy are now a standard of care in resectable early-stage NSCLC. However, further improvements in pathological complete response (pCR) and survival outcomes are still needed. IPH5201, a humanized anti-CD39 neutralizing antibody, is designed to enhance antitumor immunity by reducing immunosuppressive adenosine and increasing immuno-activating ATP levels, as demonstrated in preclinical models. In the ongoing Phase 2 MATISSE study: 40 patients with stage II–IIIA NSCLC were treated The regimen demonstrated a safety profile comparable to preoperative platinium-based chemo+durvalumab The observed pathological Complete Response (pCR) rates were: 5% in the overall population 7% in patients with PD-L1 ≥1% 50% in patients with PD-L1 ≥50% These results compare favorably with historical data from the AEGEAN Phase 3 study. Biomarker analyses confirmed CD39 target engagement and suggested a correlation between CD39+ tumor cell density and treatment response. These findings support the continuation of the study, including ongoing recruitment of patients with PD-L1 ≥1%. About IPH5201 antibody IPH5201 is a first-in-class-humanized CD39 blocking antibody codeveloped by Innate Pharma and AstraZeneca (AZ). OREGA Biotech entered into an exclusive and worldwide License Agreement with Innate Pharma in 2016. The lead antibody (IPH5201) has been further partnered with AstraZeneca in 2018. AstraZeneca conducted a multicenter, open-label, dose-escalation Phase 1 trial in advanced solid tumors (NCT04261075) with IPH5201 alone or in combination with durvalumab (anti PD-L1 antibody). About NCT05742607 clinical trial MATISSE is a Phase 2 multicenter single-arm study (NCT05742607) evaluating neoadjuvant and adjuvant treatment with IPH5201 in combination with durvalumab (anti-PD-L1, AZ) and chemotherapy in treatment-naïve patients with resectable early-stage non-small cell lung cancer (NSCLC). The primary objectives of the study are to assess antitumor activity of neoadjuvant treatment based on pathological complete response (pCR) and safety. About OREGA Biotech OREGA Biotech specializes in the discovery and the development of first-in-class monoclonal antibodies for cancer immunotherapy. Our in vivo screening platform aims at discovering and validating novel immune checkpoint inhibitors and regulators of anti-PD1 response. Incepted in 2010, OREGA […]

Lyon, France, April 17th, 2026 – OREGA Biotech, the biotech company committed to the discovery of novel immuno-oncology targets for cancer immunotherapy, reported today that the AACR 2026 abstract reporting interim results from the phase 2 MATISSE trial of IPH5201 plus durvalumab (durvalumab) and platinum-based chemotherapy in patients with resectable early stage non-small cell lung cancer (NSCLC) has been published. Summary of the abstract: Perioperative PD-(L)1 inhibitors combined with chemotherapy are now standard for resectable early-stage NSCLC, but further improvements in pathological complete response (pCR) and survival are still needed. IPH5201, an anti-CD39 antibody, aims to enhance antitumor immunity by reducing immunosuppressive adenosine and increasing ATP levels. In the Phase 2 MATISSE study, IPH5201 was added to durvalumab and chemotherapy in patients with stage II–IIIA NSCLC. Among 40 patients, the treatment showed a favorable safety profile and achieved a pCR rate of 27.5% (all), rising to 35.7% in PD-L1 ≥1% and 50% in PD-L1 ≥50% patients, comparing favorably with the 17.2%, 21.2% and 27.5% reported for durvalumab + chemo in the AEGEAN study (Heymach, 2023). Biomarker analyses confirmed CD39 target engagement and suggested a link between CD39+ tumor cell density and response. These results compare favorably to prior standards and support the continuation of the study with the recruitment of PD-L1≥1% pts. Presentation details: Session CTPL04 – Advances in Immunotherapy CT231 – Dual CD39 and PD-L1 inhibition: Interim results from the phase 2 MATISSE trial of IPH5201 plus durvalumab (durva) and platinum-based chemotherapy (CT) in patients (pts) with resectable NSCLC. Session Date/Time: April 21, 2026, 10:45 AM – 11:00 AM Hall H – Ground Level – Convention Center Presenter: Pr. Fabrice Barlesi, CEO of Institut Gustave Roussy   About IPH5201 antibody IPH5201 is a humanized CD39 blocking antibody codeveloped by Innate Pharma and AstraZeneca (AZ). OREGA Biotech entered into an exclusive and worldwide License Agreement with Innate Pharma in 2016. The lead antibody (IPH5201) has been further partnered with AstraZeneca in 2018. AstraZeneca conducted a multicenter, open-label, dose-escalation Phase 1 trial in advanced solid tumors (NCT04261075) with IPH5201 alone or in combination with durvalumab (anti PD-L1 antibody). About NCT05742607 clinical trial MATISSE is a Phase 2 multicenter single-arm study (NCT05742607) evaluating neoadjuvant and adjuvant treatment with IPH5201 in combination with durvalumab (anti-PD-L1, AZ) and chemotherapy in treatment-naïve patients with resectable early-stage non-small cell lung cancer (NSCLC). The primary objectives of the study are to assess antitumor activity of neoadjuvant treatment […]

Jeremy BASTID, CEO of OREGA Biotech, will participate in the upcoming AACR annual meeting to be held on April 17 – 22, 2026 in San Diego, California.

Jeremy BASTID, CEO of OREGA Biotech, will attend the upcoming CICON24 meeting to be held at the Gaylord National Resort & Convention Center in National Harbor, MD (Washington, DC area) September 8-11, 2024.